1. Pharmaceuticals and Drug Development

Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

REDWOOD CITY, Calif.–(BUSINESS WIRE)–Dec. 31, 2025– Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and…

Comments to: Corcept Receives Complete Response Letter for Relacorilant as a Treatment for Patients with Hypercortisolism

Login

Welcome to Life Science News!

"Explore the Latest Discoveries and Breakthroughs in Life Science with Life Science News!"
Read Smart, Save Time
Pick all the topics you are interested in to fill your homepage with stories you'll love.
Join our community
Registration is closed.